Table 1.
Description of studies included in the review of factors associated with quality of life and psychological functioning in patients with PMBT
| Authors, Year | Outcomes of Interest (measures) | Independent Variables with Statistical Significance (P < .05)a | Quality Score |
|---|---|---|---|
| Arnold et al, 200833 | Depression (mPHQ); generalised anxiety (mPHQ) | Sex; tumor grade; history of mental health difficulties; education | 9/16 |
| Brown et al, 200550 | QoL (LASA, FACT-Br); depression (POMS-SF) | Fatigue; sleep quality; depression; extent of resection; AED use | 10/16 |
| Daigle et al, 201348 | QoL (SNAS) | Extent of resection; tumor volume; pain | 10/16 |
| Fox et al, 200710 | Depression (HADS); QoL (FSQoLS) | Fatigue; sleep quality; cognitive function; depression; QoL | 12/16 |
| Giovagnoli et al, 199640 | QoL (FLIC); anxiety (STAI); depression (SRDS) | KPS; functional impairment; anxiety; depression; education; tumor site | 10/16 |
| Giovagnoli, 199939 | QoL (FLIC); anxiety (STAI, STAI-2); depression (SRDS) | Anxiety; depression; KPS; cognitive function | 11/16 |
| Giovagnoli et al, 200534 | QoL (FLIC); anxiety (STAI, STAI-2); depression (SRDS) | Tumor grade | 9/16 |
| Hahn et al, 200346 | Depression (BDI); QoL (LASA, MHS, HUS) | Tumor laterality | 10/16 |
| Halkett et al, 201541 | Distress (DT); QoL (FACT-Br, FACT-G) | Education; functional impairment | 13/16 |
| Kaplan and Miner, 200035 | Depression (BDI, MAS); anxiety (BAI, STAI) | Anxiety | 9/16 |
| Keir et al, 200813 | Distress (DT) | Sex | 13/16 |
| Kilbride et al, 200743 | Anxiety (HADS); depression (HADS) | No findings of statistical significance | 9/16 |
| Klein et al, 200147 | QoL (SF-36, QLQ-BN20) | Extent of resection; corticosteroid use | 11/16 |
| Kvale et al, 200914 | Distress (DT) | QoL | 12/16 |
| Lin et al, 201351 | Depression (POMS-SF); anxiety (POMS-SF). | Uncertainty; KPS | 11/16 |
| Litofsky et al, 200420 | Depression (SF-36, 3-item binary measure, physician report) | KPS; tumor site; tumor volume; corticosteroid use; consciousness problems; headache; memory loss; personality change; motor deficits; cognitive changes; papilledema | 11/16 |
| Porter et al, 201442 | QoL (FACT-Br, FP-QLI) | TFD; marital statusb | 10/16 |
| Osoba et al, 199749 | QoL (QLQ-C30) | Functional impairment; recurrence; motor deficits | 11/16 |
| Raysi Dehcordi et al, 201236 | Depression (BDI) | Tumor site; KPS | 12/16 |
| Rooney et al, 201118 | Depression (SCID) | History of mental health difficulties; KPS; corticosteroid use; cognitive impairment | 14/16 |
| Rooney et al, 201345 | Distress (DT) | Depression; functional impairment; AED use; extent of resection; age | 10/16 |
| Weitzner et al, 199644 | QoL (FP-QLI, PAIS-SR) | Marital status; tumor laterality | 9/16 |
| Yavas et al, 201238 | QoL (QLQ-C30, QLQ-BN20); anxiety (HADS); depression (HADS) | Sex; tumor grade | 11/16 |
Abbreviations: AED, Anti-epileptic drug; BAI, Beck Anxiety Inventory; BDI, Beck Depression Inventory; DT, Distress Thermometer; FACT-Br, Functional Assessment of Cancer Therapy - Brain; FACT-G, Functional Assessment of Cancer Therapy – General; FLIC, Functional Living Index - Cancer; FP-QLI, Ferrans and Powers Quality of Life Index for Cancer; FSQoLS, Fox Simple Quality of Life Scale; HADS, Hospital Anxiety and Depression Scale; HUS, Hassles and Uplifts Scale; KPS, Karnofsky Performance Scale; LASA, Linear analogue scale assessment; MAS, Mood Assessment Scale; MHS, Miller Hope Scale; mPHQ, Modified Patient Health Questionnaire; PAIS-SR, Psychosocial Adjustment to Illness Scale - Self Report; POMS-SF, Profile of Mood States - Short Form; QLQ-C30, Quality of Life Questionnaire for Cancer-30; QLQ-BN20, Quality of Life Questionnaire for Cancer – Brain Cancer Module; SCID, Structured Clinical Interview for DSM-IV Disorders; SF-36, Short Form (36) Health Survey; SNAS, Sherbrooke Neuro-oncology Assessment Scale; SRDS, Zung Self-Rating Depression Scale; STAI-1, State Trait Anxiety Inventory; STAI-2, State Trait Anxiety Inventory-2; TFD, Time from diagnosis.
aFull details of all relevant findings from each study included in the review are listed in Supplementary material, Table S2.
bThe authors report significant findings at the level of P < .1. To maintain consistency with the other studies reviewed, we will only consider findings of this study statistically significant at P < .05.